Kalirin Promotes Neointimal Hyperplasia by Activating Rac in Smooth Muscle Cells


Objective—Kalirin is a multifunctional protein that contains 2 guanine nucleotide exchange factor domains for the GTPases Rac1 and RhoA. Variants of KALRN have been associated with atherosclerosis in humans, but Kalirin’s activity has been characterized almost exclusively in the central nervous system. We therefore tested the hypothesis that Kalirin functions as a Rho-guanine nucleotide exchange factor in arterial smooth muscle cells (SMCs).

Approach and Results—Kalirin-9 protein is expressed abundantly in aorta and bone marrow, as well as in cultured SMCs, endothelial cells, and macrophages. Moreover, arterial Kalirin was upregulated during early atherogenesis in apolipoprotein E-deficient mice. In cultured SMCs, signaling was affected similarly in 3 models of Kalirin loss-of-function: heterozygous Kalrn deletion, Kalirin RNAi, and treatment with the Kalirin Rho-guanine nucleotide exchange factor -1 inhibitor 1-(3-nitrophenyl)-1H-pyrole-2,5-dione. With reduced Kalirin function, SMCs showed normal RhoA activation but diminished Rac1 activation, assessed as reduced Rac-GTP levels, p21-activated kinase autophosphorylation, and SMC migration. Kalrn+/− SMCs proliferated 30% less rapidly than wild-type SMCs. Neointimal hyperplasia engendered by carotid endothelial denudation was ≈60% less in Kalrn+/− and SMC-specific Kalrn−/− mice than in control mice.

Conclusion—Kalirin functions as a guanine nucleotide exchange factor for Rac1 in SMCs, and promotes SMC migration and proliferation both in vitro and in vivo. (Arterioscler Thromb Vasc Biol. 2013;33:702-708.)

Key Words: guanine nucleotide exchange factors ■ neointimal hyperplasia ■ signal transduction ■ smooth muscle cells

Human atherosclerosis has been associated with variants of the gene KALRN in several independent human cohorts,1-3 yet the function of the proteins encoded by KALRN—Kalirin isoforms—has been studied almost exclusively in neurons and pituitary cells. The most abundantly expressed Kalirin isoform outside the central nervous system is Kalirin-9, for which mRNA is detectable in aorta, liver, and skeletal muscle of adult mice.4 A 270-kDa protein, Kalirin-9 is one of only 2 mammalian proteins that contain 2 GDP/GTP exchange factors (GEFs) for the Rho family GTPases, which are critical for cytoskeletal dynamics and consequently for cell motility and proliferation.5 Phylogenetic conservation from C. elegans to human attests to the importance of Kalirin-9 in cell biology.6 Kalirin-9 comprises an N-terminal phospholipid-biding Sec14p domain followed by 9 spectrin repeats, its RhoGEF1 domain, a Src-homology 3 (SH3) domain, its RhoGEF2 domain, and a second SH3 domain (Figure 1A).6 Whereas the RhoGEF1 domain of Kalirin activates Rac1 and RhoG, the RhoGEF2 domain activates RhoA.6 The spectrin repeats are known thus far to bind to the N-terminal region of inducible nitric oxide synthase (NOS2),7 to peptidylglycine α-amidating monoxygenase, Huntingtin-associated protein-1, Disrupted-in-Schizophrenia 1, Arf6, sorting nexins 1 and 2, andcdc26-spectrin.8-9 Kalirin has one mammalian ortholog, named Trio, with which Kalirin shares 65% to 85% amino acid identity in the RhoGEF domains.6 Nevertheless, Kalirin and Trio are not interchangeable: Trio−/− and Kalrin−/− mouse embryos die during development on the 129/C57BL/6 mixed genetic background,4,6 and Kalrin−/− mice show diminished size and multiple abnormalities on the C57BL/6 background.4

See accompanying editorial on page 667

Kalirin’s RhoGEF activity could plausibly augment atherogenesis by enhancing vascular smooth muscle cell (SMC) proliferation and migration,8-11 and endothelial dysfunction,12 among other mechanisms. Of the 60 to 70 RhoGEFs encoded by mammalian genomes,13 27 are expressed as mRNAs in SMCs,14 but only a third of these have been shown to serve unique functions in SMCs.14-16 By activating Rac1 in SMCs, Kalirin’s RhoGEF1 activity could promote SMC migration and proliferation by activating the p21-activated (Ser/Thr) kinase (PAK),20-22 and NADPH oxidases.23 By activating RhoA, Kalirin’s RhoGEF2 activity could promote not only SMC migration and proliferation,24
Vascular and bone marrow-derived cells express Kalirin-9, which is upregulated during atherogenesis. A, A scale drawing of the domain topography of Kalirins -9 and -12 (named for the size of their mRNA). DH-1 indicates Db (deleted in B-cell lymphoma) homology-1; Ig, immunoglobulin; Kinase, Ser/Thr kinase; PH, pleckstrin homology; Sec14p, phospholipid-binding; and SH3, Src homology 3. B, The indicated tissues and primary cell lines from wild-type (WT) mice were solubilized; 35 μg of protein was subjected to SDS-PAGE and immunoblotted with anti (Kalirin spectrin domain)-IgG. Parallel blots probed with nonimmune first IgG yielded no bands (not shown). Arrows indicate Kalirin isoforms. Shown is a single experiment, representative of 3 performed. C, Mice of the indicated genotype were euthanized; 35 μg of tissue was immunoblotted for Kalirin, as panel B. The nitrocellulose was stripped and reprobed for G protein-coupled receptor kinase-2 (GRK2) as a loading control. Shown are immunoblots representative of 3 independent experiments.

Materials and Methods

Materials and methods are available in the online-only Supplement.

Results

Vascular Expression of Kalirin

To delineate potential loci of Kalirin activity in vascular biology, we first immunoblotted mouse tissues and cells to determine their Kalirin-expression levels relative to those obtained in mouse brain. As Figure 1B shows, primary SMCs, endothelial cells, and macrophages all express Kalirin-9 at levels comparable with those obtained from mouse brain, and similar findings were obtained by using extracts from mouse aorta or bone marrow. In contrast, aortas from Kalrn−/− mice demonstrated no immunoreactivity corresponding to Kalirin-9 (Figure 1C). To determine whether Kalirin expression changed in the context of atherogenesis, we compared thoracic aortas from WT and Apoe−/− mice aged 8 weeks, before intimal macrophage infiltration occurs.25 Kalirin-9 protein expression was 1.6±0.2-fold higher in aortas from Apoe−/− than from WT mice (P<0.05; Figure 1C). Thus, vascular cell expression of Kalirin-9 is upregulated during the earliest stages of atherogenesis.

Kalirin Activates Rac1 in SMCs

To test whether Kalirin function affects SMC physiology, we first inhibited Kalirin’s RhoGEF1 domain by treating primary SMCs with the cell-permeant compound NPPD (1-(3-nitrophenyl)-1H-pyrrole-2,5-dione), which selectively inhibits GDP/GTP exchange activity promoted by the highly homologous RhoGEF1 domains of Kalirin and its lone ortholog, Trio.26 Kalirin’s RhoGEF1 and RhoGEF2 domains activate Rac1 and RhoA, respectively (Figure 1A).6 We therefore assessed SMC Rac1 and RhoA activity, by determining the activity of their respective effector kinases: PAK1, which when activated by Rac1-GTP autophosphorylates on Thr-423;27 and Rho-associated coiled-coil–containing protein kinases (ROCK1, ROCK2), which when activated by RhoA-GTP phosphorylate the myosin phosphatase-targeting subunit 1 (MYPT1) on Thr-853.28 PAK1 autophosphorylation induced by platelet-derived growth factor (PDGF) was reduced by 40±20% (P<0.05) in SMCs treated with NPPD (Figure 2A and 2B). In contrast, (ROCK-mediated) MYPT1 phosphorylation was not affected by NPPD (Figure 2A and 2B). Thus, the RhoGEF1 domain of Kalirin or Trio—known to activate Rac1, but not RhoA6—appears to mediate Rac1 activation downstream of the PDGF receptor in SMCs. To distinguish Kalirin from Trio in this NPPD-sensitive SMC Rac1 activation, we compared Kalirin and Trio expression in SMCs with that in brain tissue, in which Trio and Kalirin are expressed at comparable levels (quantitative real-time PCR data not shown). Whereas SMC Trio protein levels were <5% of brain levels, SMC Kalirin protein levels were comparable with those in brain tissue (Figure 2C). Consequently, we inferred that most of the NPPD-inhibited, PDGF-induced Rac-GEF activity in SMCs is attributable to Kalirin, rather than to Trio.

To complement NPPD-mediated inhibition of Kalirin’s RhoGEF1 domain, and to determine whether Kalirin’s RhoGEF2 domain is also important in SMC physiology, we used Kalirin RNAi. Relative to SMCs transfected with control small interfering RNA, SMCs transfected with Kalirin-targeting small interfering RNA demonstrated 43±9% less Kalirin protein expression and 50±20% less PAK1 autophosphorylation in response to PDGF or serum (P<0.05; Figure 2D–2F). Nevertheless, Kalirin knockdown SMCs demonstrated MYPT1 phosphorylation (evidence of ROCK activity)28 that was equivalent to control SMCs (Figure 2E and 2F). Thus, we obtained equivalent results in SMCs with
Kalirin knockdown and chemical inhibition of Kalirin’s RhoGEF1 domain, and Kalirin appears to function in SMCs as an important GEF for Rac1, but not for RhoA.

To corroborate these data obtained with Kalirin RNAi, we used 5 independently isolated lines of SMCs from age- and sex-matched Kalrn+/− and littermate WT mice. Kalrn+/− SMCs expressed only 45±5% as much Kalirin-9 protein as WT SMCs, but equivalent levels of proteins critical for the receptor tyrosine kinase and (heterotrimeric) Gq/11 signal transduction pathways under investigation: PDGF receptor-β, endothelin receptor type A, Rac1, RhoA, PAK1, and MYPT1 (Figure 3A).

β pathways under investigation: PDGF receptor-β, endothelin receptor type A, Rac1, RhoA, PAK1, and MYPT1 (Figure 3A).

When stimulated with serum, PDGF, or endothelin-1, Kalrn+/− SMCs demonstrated only ≈60% of WT PAK1 activation, as assessed by PAK1 autophosphorylation (Figure 3B and 3C). In contrast, Kalrn+/− SMCs demonstrated WT levels of ROCK activation, as assessed by MYPT1 phosphorylation35 (Figure 3B and C). Because ROCK isoforms can be activated not only by RhoA (the target of Kalirin’s RhoGEF2 domain), but also by RhoB and RhoC,29 we also assessed SMC RhoA-GTP levels. Consistent with MYPT1 phosphorylation data, Kalrn+/− and WT SMCs demonstrated equivalent, 2- to 3-fold over basal stimulation of RhoA-GTP loading in response to serum (Figure 3D). In contrast, Kalrn+/− SMCs demonstrated 30% less Rac1-GTP loading than WT SMCs (Figure 3D). Thus, assessed at the level of the GTPase or the effector kinases, Kalirin appears to promote the activation of Rac1, but not RhoA, in SMCs.

Kalirin Promotes SMC Migration and Proliferation

Because Rac1 and PAK1 signaling are critical for SMC migration,20,21 we reasoned in light of Figure 3 that loss of Kalirin function would reduce SMC migration. To test this hypothesis, we studied SMC migration in modified Boyden chambers. Stimulus-independent SMC migration was not affected by loss of Kalirin function (Figure 4). However, whether engendered by chemical inhibition of Kalirin’s RhoGEF1 domain (by NPPD), by Kalirin RNAi, or by Kalirin haploinsufficiency, loss of Kalirin function was associated with a ≈35% reduction in PDGF- or serum-evoked SMC migration (P<0.05; Figure 4). To determine whether loss of Kalirin function reduced SMC migration principally by reducing Rac1 activation, we treated SMCs with the cell-permeant Kalirin RhoGEF1 inhibitor ITX334 or the Rac1 inhibitor Z62954982, using conditions that have been shown to inhibit PDGF-induced GTP loading of Rac1 by ≈50% without affecting GTP loading of the related Rho-GTPases Cdc42 or RhoA.35 Kalirin RhoGEF1 or Rac1 inhibition with ITX3 or Z62954982, respectively, reduced by 35% to 40% the migration of WT SMCs stimulated by PDGF (Figure 4D). This attenuation of SMC migration was comparable with that seen with the loss of Kalirin function observed in Kalrn−/− SMCs. Furthermore, the impaired migration of Kalrn−/− SMCs was not further reduced by ITX3 or Z62954982 (Figure 4D). In parallel experiments with WT SMCs, Z62954982 inhibited PAK1 autophosphorylation by 40±10%, but neither ITX3 nor Z62954982 inhibited ROCK activity, manifest as MYPT1 phosphorylation, or mitogen-activated or extracellular signal-regulated protein kinase kinase-1 activity, manifest as phosphorylation of extracellular signal-regulated kinase-1 and -2 (Figure 4E and data not shown). As a further demonstration of inhibitor specificity, neither ITX3 nor Z62954982 reduced the SMC migration promoted by fetal bovine serum under the conditions prevailing in these experiments (Figure 4D). Taken together, these data suggest that Kalirin mediates Rac1 activation in SMCs downstream of the PDGF receptor, and thereby promotes SMC migration.

Whereas cellular migration can be promoted by Rac1 activity at the plasma membrane,20 cellular proliferation appears to require Rac1 nuclear localization.32 Thus, despite

---

**Figure 2.** Smooth muscle cell (SMC) Kalirin activates Rac1, but not RhoA; inhibitor and RNAi data. A, Quiescent aortic SMCs were treated for 2.5 hours with 0.1% dimethyl sulfoxide lacking (control) or containing the Kalirin RhoGEF1 domain inhibitor NPPD (1-(3-nitrophenyl)-1H-pyrrole-2,5-dione; 100 μmol/L [final]). Subsequently, SMCs were exposed to serum-free medium lacking (None) or containing 1 mmol/L platelet-derived growth factor (PDGF)-BB (10 minutes, 37°C), solubilized, and immunoblotted for phospho- (p-) p21-activated (Ser/Thr) kinase (PAK)1 (p-Thr423), p-myosin phosphatase-targeting subunit 1 (MYPT1; p-Thr653), and then for G protein-coupled receptor kinase-5 (GRK5; as a loading control). B, The indicated phosphoprotein band densities were normalized to cognate GRK5 bands on each blot; quotients from Kal-small interfering RNA–transfected SMCs were divided by those obtained from control-transfected SMCs within the same experiment to obtain percentage of control, plotted as means±SE of 3 experiments. Compared with control: *P<0.05.

---

**Figure 3.** Kalirin knockdown and chemical inhibition of Kalirin’s RhoGEF1 domain, and Kalirin appears to function in SMCs as an important GEF for Rac1, but not for RhoA. A, Rac1, RhoA, PAK1, and MYPT1 (Figure 3A).
the observation that Kalirin promoted Rac1-dependent SMC migration, the effects of Kalirin on SMC proliferation remained uncertain. To test whether Kalirin activity promotes SMC proliferation, therefore, we quantitated WT and \( \text{Kalrn}^{-/-} \) SMCs at several time points during exposure to serum. \( \text{Kalrn}^{-/-} \) SMCs proliferated 50% less rapidly than WT SMCs in response to serum (\( P < 0.03 \); Figure 5). Thus, Kalirin appears to promote SMC proliferation.

SMC Kalirin Promotes Neointimal Hyperplasia

SMC proliferation and migration are fundamental to the neointimal hyperplasia that develops in response to arterial endothelial denudation. If Kalirin’s positive effects on SMC migration and proliferation occurred not only in vitro, but also in vivo, we reasoned that \( \text{Kalrn}^{-/-} \) mice should develop less neointimal hyperplasia than WT mice. We therefore sought to ascertain that SMC Kalirin activity, specifically, was promoting the in vivo SMC proliferation and migration of neointimal hyperplasia. To do so, we used mice with SMC-specific deletion of Kalirin (SMC-\( \text{Kalrn}^{-/-} \)), or SM22a-Cre/\( \text{Kalrn}^{fl/+} \)) mice, and compared them with \( \text{Kalrn}^{fl/+} \) control mice (which gave results equivalent to WT mice [data not shown]). Compared with WT or \( \text{Kalrn}^{fl/+} \) control mice, SMC-\( \text{Kalrn}^{-/-} \) mice expressed Kalirin-9 protein levels that were 50±5% less in endothelium-stripped aortas, but equivalent in whole-brain extracts (Figure 6A). After carotid endothelial denudation, SMC-\( \text{Kalrn}^{-/-} \) mice developed 65% less neointimal hyperplasia than in either control mouse cohort (Figure 6B and 6C). Before surgery, \( \text{Kalrn}^{-/-} \), SMC-\( \text{Kalrn}^{-/-} \), and WT mice had equivalent carotid dimensions (data not shown) and equivalent systolic blood pressures and heart rates: respectively, 121±7, 120±10, and 120±10 mm Hg; 700±40, 640±40, and 660±40 bpm (n=7/group). Thus, whether in SMCs alone or in combination with endothelial cells and leukocytes, Kalirin activity contributes to neointimal hyperplasia.

![Figure 3](http://ahajournals.org/) Smooth muscle cell (SMC) Kalirin activates Rac1, but not RhoA; data from \( \text{Kalrn}^{-/-} \) and wild-type (WT) SMCs. A, Solubilized extracts (40 μg protein/lane) from WT (\( \text{Kalrn}^{+/+} \)) and \( \text{Kalrn}^{-/-} \) SMCs were immunoblotted serially for the indicated proteins: platelet-derived growth factor receptor β (PDGFRβ); endothelin receptor subtype A (ET\(_{\alpha}\)-R). Shown are results from a single experiment representative of 5 performed. B, Quiescent SMCs from WT or \( \text{Kalrn}^{+/+} \) mice were exposed for 10 minutes (37°C) to serum-free medium lacking (None) or containing 10% FBS, 2 nmol/L PDGF-BB, or 100 nmol/L endothelin-1 (ET-1), then solubilized and immunoblotted for the indicated (phospho) proteins. PLC\( \gamma \) (phospholipase C-\( \gamma \)) was used as a loading control. Shown are results from a single experiment, representative of 5 performed. C, The indicated phosphoprotein band densities were normalized to cognate PLC\( \gamma \) bands; quotients were divided by those of WT SMCs to obtain percentage of WT, plotted as means±SE of 5 experiments with independently isolated WT and \( \text{Kalrn}^{-/-} \) SMC lines. Compared with WT: *\( P<0.05 \). D, Quiescent WT and \( \text{Kalrn}^{-/-} \) SMCs were stimulated as in panel B, lysed, and subjected to RhoA or Rac1 G-LISA (Cytoskeleton, Inc). Absorbance values were normalized in each experiment to the value obtained for FBS-stimulated WT SMCs, to obtain percentage of control. Shown are the means±SE from ≥3 experiments performed in triplicate. Compared with WT: *\( P<0.05 \).
This study establishes Kalirin, a human atherosclerosis candidate gene, as a significant signaling intermediate that promotes SMC Rac1 activation, migration, and proliferation downstream of the PDGF receptor-β and G protein-coupled receptors in vitro (Figure VII in the online-only Data Supplement). Consonant with this signaling activity in SMCs, Kalirin in vivo promotes neointimal hyperplasia induced by arterial endothelial denudation—whether Kalirin expression is manipulated globally, or just in SMCs. It is noteworthy that Kalirin’s role in vascular biology manifests with loss-of-function models that allow ≈50% of normal Kalirin activity. Consequently, the magnitude of Kalirin’s total contribution to vascular pathophysiology may be underestimated by these models; nevertheless, incomplete loss-of-function models human disease and pharmacotherapeutic responses better than complete loss-of-function.1–3

Kalirin-promoted SMC migration and proliferation correlate with Kalirin’s Rac1-GEF activity, triggered by the PDGF receptor-β: indeed, Kalirin deficiency impaired SMC migration only when Rac1 activity was intact (Figure 4). In neurons, Kalirin Rac-GEF activity is triggered by the receptor tyrosine kinase EphB2, which tyrosine-phosphorylates and recruits Kalirin to the plasma membrane.34 Whether this method of Kalirin activation occurs downstream of the PDGF receptor-β tyrosine kinase remains to be established. However, SMCs express both EphB2 and its agonist ephrinB2, which appear to promote SMC migration in vivo;35 thus, Kalirin could mediate SMC migration in vivo downstream of multiple receptor tyrosine kinases. Furthermore, because EphB2 receptors on monocytes promote adhesion to arteries and because monocyte/macrophages express abundant Kalirin (Figure 1), it is conceivable that an EphB2–Kalirin signaling axis operates in monocytes to promote monocyte/macrophage infiltration of the (ephrinB2-expressing)35 tunica media of injured arteries. Because monocyte/macrophages contribute significantly to neointimal hyperplasia,36 Kalirin deficiency in monocytes could thus contribute to the reduction in neointimal hyperplasia we observed in Kalrn–/+ as compared with WT mice (Figure 6).

Despite containing a GEF domain specific for Rac1 and a GEF domain specific for RhoA,4 Kalirin appears to function in SMCs as a GEF only for Rac1, and not for RhoA. This inference is based on comparisons among SMCs with Kalirin levels that were either 100% or ≈50% of WT; consequently, it may be that 50% of normal Kalirin levels in SMCs suffice to...
drive normal activation of RhoA, but not Rac1. Alternatively, Kalirin’s apparent Rho-family GTPase specificity in SMCs may result from distinct subcellular distributions, and overlapping functions of the myriad Rac1- and RhoA-GEFs expressed along with Kalirin in SMCs.14–19 Lastly, it is important to note that the overall GTPase activity reflects a balance between the activities of GEFs, which activate GTPases by promoting the exchange of GTP for GDP, and GTPase-activating proteins, which deactivate GTPases by enhancing hydrolysis of GTP to GDP.5 Thus, it may be that the functionality of GTPase-activating proteins for Rac1 exceeds that of GTPase-activating proteins for RhoA in SMCs; if so, we could ascertain differences in Kalirin-mediated activation of Rac1 more sensitively than we could for RhoA.

Kalirin may also contribute to neointimal hyperplasia through mechanisms distinct from its Rac1-GEF activity. For example, Kalirin’s interaction with the N-terminal domain of NOS2 prevents NOS2 dimerization, and thereby inhibits NOS2 activity.7 Perhaps because NOS2-produced NO reduces SMC proliferation and mitochondrial respiration,37 Nos2−/− mice develop more medial thickening than WT mice subjected to carotid endothelial denudation.38 Consequently, by inhibiting SMC NOS2, Kalirin could reduce NO−-mediated inhibition of SMC proliferation—and thereby contribute to neointimal hyperplasia. Whether such a mechanism occurs in SMCs remain to be established.

Achieved either genetically or by RNAi, just a 50% reduction in Kalirin activity suffices to reduce SMC proliferation and migration in vitro and in vivo. Consequently, Kalirin appears to be an appealing target for pharmacotherapy in SMC-proliferative disorders like neointimal hyperplasia. Because interventions that diminish neointimal hyperplasia often diminish atherosclerosis, too,24,39 the work presented here adds credence to human genetic data implicating Kalirin in atherogenesis. Direct evidence to support Kalirin’s role in atherosclerosis, of course, has yet to manifest.

Sources of Funding
This work was supported by NIH grants HL77185 and HL73005 (N.J.F.), DK32948 (B.A.E., R.E.M.), a Howard Hughes Medical Institute Medical Student Fellowship (A.C.F), and an American Heart Association Grant-in-Aid (L.Z.).

Disclosures
None.

References
Variants of the gene encoding Kalirin have been associated with atherosclerosis, but the function of Kalirin in vascular or immune cells remains enigmatic. Kalirin is a large scaffolding protein that also contains 2 domains that activate the Rho family of monomeric G proteins. We demonstrated that Kalirin is expressed in vascular cells and macrophages. Furthermore, in vascular smooth muscle cells stimulated by the atherogenic agonist platelet-derived growth factor, Kalirin activates the G protein Rac1 and thereby promotes smooth muscle cell proliferation and migration. Deficiency of Kalirin even just in smooth muscle cells suffices to reduce pathologic smooth muscle cell migration and proliferation in endothelium-denuded carotid arteries. Thus, Kalirin seems to play an important role in vascular pathology and may contribute to atherosclerosis.
Kalirin Promotes Neointimal Hyperplasia by Activating Rac in Smooth Muscle Cells

Arterioscler Thromb Vasc Biol. 2013;33:702-708; originally published online January 3, 2013; doi: 10.1161/ATVBAHA.112.300234
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/33/4/702

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2013/01/03/ATVBAHA.112.300234.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
Expanded Methods

Materials
The Kalirin RhoGEF1-selective inhibitor NPPD (1-(3-nitrophenyl)-1H-pyrrrole-2,5-dione) was obtained from Chembridge, Inc. The Kalirin RhoGEF1-selective inhibitor ITX3 (2-[(2,5-Dimethyl-1-phenyl-1H-pyrrol-3-yl)methylene]-thiazolo[3,2-a]benzimidazol-3(2H)-one) was obtained from Sigma-Aldrich, Inc. The Rac1 inhibitor Z62954982 (3-((3,5-Dimethyloxazol-4-yl)methoxy)-N-(4-methyl-3-sulfamoylphenyl)benzamide) was obtained from EMD Millipore. Cell culture supplies were from Invitrogen, unless specified otherwise. Human PDGF-BB was from Millipore.

Antibodies against the following proteins were from the following sources: phospho- (p-)Thr423-PAK (sc-12925), total PAK1 (sc-881), PLC-γ1 (sc-7290), actin c-19 (sc-1616), PDGFRβ (sc-432), RhoA (clone 26C4, sc-418), and β-Tubulin (sc-9104) were all from Santa Cruz Biotechnology; p-Thr853-MYPT1 (rabbit polyclonal, #4563) and p-ERK1/2 (clone E10) were from Cell Signaling, Inc.; MYPT1 (07-672) and Rac1 (clone 23A8) were from Millipore; endothelin receptor subtype A (ETA-R) was from Alomone Labs, Inc.; SMC-actin (clone 1A4, conjugated to Cy-3), PCNA (clone PC10), and collagen I (clone COL-1) were obtained from Sigma-Aldrich; CD11b (clone M1/70) and isotype control IgG conjugated to phycoerythrin were obtained from BioLegend, Inc.; von Willebrand factor (vWF) was obtained from DakoCytomation (rabbit polyclonal #A0082); GRK5 (clone A16/17) was produced as described. Polyclonal rabbit antisera specific for the Kalirin spectrin domain (spectrin-like repeats 4-7) or Trio3 were produced as described.

Mice
All mice were congenic (≥10 generations back-crossed) on the C57BL/6 background. Kalrn<sup>flox/+</sup> mice harbored a Kalrn allele containing loxP sites flanking exon 13 (of the spectrin repeat domain); they were produced as described, and crossed with FLPeR mice to remove the neomycin resistance cassette. It is important to note that knockout of Kalrn exon 13 prevents the synthesis of all Kalirin isoforms except the minor species known as delta-Kalirin-9 and Duet. These mice were crossed with CMV-Cre-transgenic mice (Jackson Labs, stock #006054) to obtain Kalrn<sup>−/−</sup> mice, which were then bred to eliminate the CMV-Cre transgene. Kalrn<sup>flox/+</sup> mice were crossed with SM22α-Cre-transgenic mice (Jackson Labs, stock #004746) to obtain mice with SMC-specific Kalrn deficiency (SM22α-Cre<sup>−/−</sup> Kalrn<sup>flox/+</sup> or SMC-Kalrn<sup>−/−</sup>). Kalrn<sup>−/−</sup> and littermate WT mice were obtained from crosses of Kalrn<sup>−/−</sup> mice. Apoe<sup>−/−</sup> mice were from Jackson Labs. All mutant mice were back-crossed to C57BL/6J WT (Jackson Labs, stock #000664) every 5 generations, to minimize genetic drift. All animal experiments complied with Duke University Institutional Animal Care and Use Committee guidelines.

Blood pressure was measured by tail cuff plethysmography with a MC4000 Blood Pressure Analysis System (Hatteras Instruments). After 10 days’ training, mice were subjected to 10 consecutive days of measurements; a single day’s measurements constituted the mean of 10 determinations made on each mouse. Hemodynamic measurements were made by an investigator unaware of mouse genotypes.

Cell Culture
Mouse aortic SMCs were isolated by enzymatic digestion of aortas and passaged as we have described. Mouse aortas were stripped of adventitia and endothelial cells, and then digested at 37 °C for 1.5 h in PBS containing the following reagents (all from Sigma): collagenase II (1 mg/ml), elastase type III (0.125 mg/ml), soybean trypsin inhibitor (0.375 mg/ml), and bovine serum albumin (fraction V, 2 mg/ml) in DMEM. Released SMCs were cultured in DMEM with 20% FBS, 1% anti-mycotic/antibiotic (Invitrogen) and 1% Mycoplasma Removal Agent (MP Biomedicals) for one wk, and then in DMEM with 10% FBS, 1% penicillin/streptomycin thereafter. SMCs were split at 1:4, and used during passages
3–7. These primary SMCs demonstrated >95% prevalence of SMC α-actin expression by immunofluorescence.

Endothelial cells were isolated from mouse aortas and cultured exactly as described. Macrophages were differentiated from bone marrow precursors with colony-stimulating factor-1, exactly as described.

**Immunoblotting**

Tissues were snap-frozen in liquid nitrogen, pulverized with a mortar and pestle, and then solubilized in SDS sample buffer or Buffer A: 50 mmol/L Tris-Cl (pH 8 at 25 °C); 1% (w/v) Triton-X-100; 0.05% (w/v) SDS; 200 mmol/L NaCl; 50 mmol/L NaF (Ser/Thr phosphatase inhibitor); 10 mmol/L disodium pyrophosphate (Ser/Thr phosphatase inhibitor); plus protease inhibitors. Cells were solubilized in either SDS sample buffer (followed by sonication) or in Buffer A. After solubilization, samples were centrifuged (10,000 × g, 10 min, 4 °C) to remove insoluble debris. Protein was quantitated in samples solubilized in Buffer A with a modified Lowry assay (BioRad), and equal protein masses were loaded in each lane for SDS-PAGE, which was performed on 4-12% polyacrylamide gradient gels or 10% polyacrylamide gels (Invitrogen). Semi-dry transfer, immunoblotting and chemiluminescent detection were performed as described. Band density was quantitated by NIH Image J.

**SMC Assays**

Proliferation and migration assays were performed on serum-starved SMCs as we described. For signaling assays, SMCs were incubated overnight (37 °C, 16 hr) in 30-mm dishes in serum-free medium (Dulbecco’s modified Eagle Medium [Invitrogen], 20 mmol/L Hepes pH 7.4, 1 mg/ml of fatty acid-free bovine serum albumin [Sigma], 100 units/ml penicillin, and 100 μg/ml streptomycin [Invitrogen]). SMCs were then stimulated for the indicated times with either 10% (vol/vol) fetal bovine serum or the indicated concentration of PDGF-BB, and then lysed in ice-cold Buffer A (above).

Quantitation of RhoA-GTP and Rac1-GTP was performed with G-LISAs (Cytoskeleton, Inc.), according to the manufacturer’s instructions.

**Carotid Endothelial Denudation**

These studies were performed as we described previously, with a 0.36-mm-diameter coronary guidewire (Cordis) using a modification of the method of Lindner et al. We used 8-wk-old WT, Kalrn−/−, and SMC-Kalrn−/+ mice matched for gender and pre-operative weight (21± 3 grams). Mice were anesthetized with pentobarbital (50 mg/kg). We created a midline neck incision extending from the lower mandible to the sternum, and then loosely tied 10-0 “control sutures” at the proximal portion of the common and internal carotid arteries and at the mid-portion of the external carotid artery, to prevent blood flow without engendering arterial wall damage. We next extended a ~0.5 mm external carotid arteriotomy from the control suture to the carotid artery bifurcation, and flushed the common carotid with PBS. To denude the endothelium, we traversed the length of the common carotid three times with a 0.36-mm flexible angioplasty guidewire (Johnson and Johnson). After removing the wire, we ligated the external carotid artery proximally after flushing the common carotid with blood, and then completely released the control sutures. Mice were sacrificed 4 wk post-operatively. At the time of sacrifice, mouse weights were equivalent in each distinct genetic group. There were no carotid thromboses in this series of mice; the overall thrombosis rate for this procedure in our hands is <2%.

**Histology/Immunofluorescence Microscopy**

Immunofluorescence was performed on OCT-embedded carotid arteries cut at 5-μm, as described. The DNA-binding fluorophore Hoechst 33342 (10 μg/ml) was added to secondary antibody incubations. To minimize elastic laminae fluorescence, we used 0.2% gelatin in both blocking and IgG diluent buffer: 20 mmol/L Tris-Cl (pH 7.5)/125 mmol/L NaCl/ 0.1% (vol/vol) Tween-20. Single microscopic fields were imaged for multiple fluorophores, and protein immunofluorescence was quantitated by normalizing to nuclear DNA fluorescence (as a measure of cellularity), exactly as described. All specimens stained within a single batch were imaged with identical CCD camera and microscope settings. In all cases,
nonspecific fluorescence (with non-immune primary IgG) was subtracted from total fluorescence, to obtain antigen-specific fluorescence. Immunofluorescence was quantitated by observers blinded to specimen identity.

Perfusion-fixed specimens were paraffin-embedded, sliced and stained with a modified Masson’s trichrome and Verhoeff’s elastic tissue stain as we previously described. Planimetry was performed with NIH Image J by observers blinded to specimen identity, as we described.

Statistical Analyses
Data are presented as mean ± S.D. in the text and as mean ± S.E. in the figures. Data from experiments with only two independent means were analyzed by *t* tests. Data from experiments with multiple groups were compared by one-way ANOVA with Tukey’s post-hoc test for multiple comparisons. Time course analyses were performed by two-way ANOVA, and SMC migration data were analyzed by repeated measures two-way ANOVA with a Bonferroni post-hoc test. Statistical software was Prism® 5 (GraphPad, Inc.).
Supplemental References


Supplemental Figure I. SMC Kalirin promotes neointimal hyperplasia (an expanded version of Figure 6). A, Figure 6B has been rendered in color here. Scale bar = 50 μm. B, Serial sections from Panel A were stained for SMC actin (red) and DNA (blue). Although SMC actin staining is variable as one would expect in samples with varying degrees of SMC activation and proliferation, all neointimal cells demonstrate SMC actin immunoreactivity. Specimens shown represent at least 5 independent specimens of each genotype. C, Figure 6C has been re-formatted here, for comparison with Panel D. Compared with WT: *, p < 0.02. D, The indicated carotid artery dimension is plotted as means ± S.E. from at least 5 carotids of each genotype. Compared with WT: *, p < 0.01; #, p < 0.05.
Supplemental Figure II. Kalirin up-regulates during neointimal hyperplasia. A, Carotid arteries from the cohort used in Figure 6, as well as contralateral uninjured carotids, were stained with rabbit IgG specific for Kalrin isoforms 7, 9, and 12, or with non-immune control rabbit IgG. Secondary incubations were with Alexa-488-conjugated anti-rabbit IgG (green) and Hoechst 33342 (DNA, blue). Scale bars = 50 μm (original magnification ×220). Shown are samples of the indicated genotype, all stained in the same batch, representative of four such sample groups. Specimens stained with non-immune rabbit IgG showed elastin autofluorescence, but no green immunofluorescence (not shown). B, Within each immunostaining group, the ratios of Kalirin immunofluorescence to DNA fluorescence intensity within the medias and neointimas were normalized to those obtained from the media of the injured WT sample(s), to yield “% of control.” Plotted are the means ± S.E. of 4 specimens of each group. Compared with Kalirin immunofluorescence in the media of WT samples: *, p < 0.05.
**Supplemental Figure III.** Kalirin promotes activation of PAK in neointimal hyperplasia. 

**A,** Serial sections of specimens from Figure 6 were stained with IgG specific for phospho-Thr423-PAK (pPAK, red) and DNA (Hoechst 33342, blue). Scale bars = 50 μm (original magnification ×220).

**B,** Neointimal phospho-PAK immunofluorescence was normalized to DNA fluorescence intensity; the resulting ratios were normalized to those of WT specimens stained in the same batch, to yield “% of WT.” The resulting ratios in each group are graphed as the means ± S.E. of 4 specimens of each group. Compared with injured WT carotid samples: *, p < 0.01.
Supplemental Figure IV. Kalirin promotes SMC proliferation in neointimal hyperplasia. A, Serial sections of specimens from Figure 6 were stained for proliferating cell nuclear antigen (PCNA, green) and DNA (Hoechst 33342, blue). Shown are individual samples, representative of 4 from each genotype. Scale bars = 50 μm (original magnification ×220). B, The number of PCNA-positive nuclei in the neointima of each specimen was normalized to the total number of neointimal nuclei, to obtain “% PCNA-positive.” Plotted are the means ± S.E. of 4 specimens from each group. Compared with injured WT carotid samples: *, p < 0.01.
Supplemental Figure V. Kalirin does not affect re-endothelialization of wire-injured carotid arteries. 

A, Serial sections of specimens from Figure 6, along with uninjured negative control carotid sections, were stained for von Willebrand factor (vWF, green) and DNA (Hoechst 33342, blue). Shown are individual samples, representative of 4 from each genotype. Scale bars = 50 μm (original magnification ×220). B, The percentage of luminal surface that stained for vWF was averaged across samples within the same genetic group, to obtain “% Re-endothelialization.” Plotted are the means ± S.E. of 4 specimens from each group.
Supplemental Figure VI. Kalirin does not affect neointimal collagen or macrophage content after carotid artery endothelial denudation. **A**, Serial sections of specimens from Figure 6 were stained for collagen I (red) and DNA (Hoechst 33342, blue). Scale bar = 50 μm (original magnification ×220). **B**, Neointimal collagen immunofluorescence was normalized to DNA fluorescence intensity; the resulting ratios were divided by those of WT specimens in the same staining batch, to yield “% of WT.” Plotted are the means ± S.E. of 4 specimens from each genetic group. **C**, Serial sections of specimens from Figure 6, along with paraffin-embedded mouse spleen, were stained with anti-CD11b or isotype control IgG (green), and Hoechst 33342 (DNA, blue). Scale bar = 50 μm (original magnification ×220). In the neointima and media, macrophage (Mφ) immunofluorescence was normalized to DNA fluorescence; the resulting ratios were divided by those of WT in the same staining batch, to yield “% of WT.” Plotted are the means ± S.E. of 4 specimens from each genetic group.
Supplemental Figure VII. Kalirin-mediated signal transduction in SMCs. Kalirin is activated downstream of the receptor tyrosine kinase for PDGF (PDGFR) in SMCs or the Gq-coupled, 7-transmembrane endothelin (ET) receptors. Kalirin’s RhoGEF1 activates Rac1 in SMCs; no evidence yet suggests that Kalirin’s RhoGEF2 can activate RhoA in SMCs as it can in neurons. Kalirin’s Rho-GEF1 is inhibited by NPPD (1-(3-nitro-phenyl)-1H-pyrrole-2,5-dione) or ITX3 (2-[2,5-Dimethyl-1-phenyl-1H-pyrrol-3-yl)methylene]-thiazolo[3,2-a]benzimidazol-3(2H)-one). Signaling to p21-activated kinase (PAK) can engender SMC proliferation by PAK-mediated phosphorylation of MEK and RAF1 (leading to ERK activation), phosphorylation of the p47phox subunit of NADPH oxidase (increasing NADPH oxidase activation), and activation of NFκB-inducing kinase (activating NFκB), among other mechanisms. Potential effects of Kalirin on Rho kinase, NADPH oxidase and inducible NO synthase (iNOS) are illustrated. Green, stimulation; red, inhibition; dotted lines, not yet demonstrated downstream of Kalirin in SMCs.